Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $62,043 | $153,731 | $67,772 | $61,880 |
| % Growth | -59.6% | 126.8% | 9.5% | – |
| Cost of Goods Sold | $7,218 | $6,816 | $8,288 | $9,773 |
| Gross Profit | $54,825 | $146,915 | $59,484 | $52,107 |
| % Margin | 88.4% | 95.6% | 87.8% | 84.2% |
| R&D Expenses | $252,043 | $180,425 | $137,171 | $104,400 |
| G&A Expenses | $48,453 | $62,584 | $59,544 | $56,004 |
| SG&A Expenses | $48,453 | $62,584 | $59,544 | $56,004 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7,218 | -$6,816 | -$8,288 | -$9,773 |
| Operating Expenses | $293,278 | $236,193 | $188,427 | $150,631 |
| Operating Income | -$238,453 | -$89,278 | -$128,943 | -$98,524 |
| % Margin | -384.3% | -58.1% | -190.3% | -159.2% |
| Other Income/Exp. Net | $13,355 | $677 | $12,239 | -$7,014 |
| Pre-Tax Income | -$225,098 | -$88,601 | -$116,704 | -$105,538 |
| Tax Expense | $2,363 | $18,192 | $2,500 | $0 |
| Net Income | -$227,461 | -$106,793 | -$119,204 | -$105,538 |
| % Margin | -366.6% | -69.5% | -175.9% | -170.6% |
| EPS | -29.6 | -17.8 | -23.5 | -22.9 |
| % Growth | -66.3% | 24.3% | -2.6% | – |
| EPS Diluted | -29.6 | -17.8 | -23.5 | -22.9 |
| Weighted Avg Shares Out | 7,683 | 6,016 | 5,074 | 4,612 |
| Weighted Avg Shares Out Dil | 7,683 | 6,016 | 5,074 | 4,612 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44,425 | $14,510 | $3,455 | $577 |
| Interest Expense | $31,070 | $23,750 | $3,346 | $3,137 |
| Depreciation & Amortization | $7,218 | $6,816 | $8,288 | $4,844 |
| EBITDA | -$180,453 | -$67,915 | -$105,070 | -$97,557 |
| % Margin | -290.9% | -44.2% | -155% | -157.7% |